Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.
Tourmaline Bio has raised $172.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2024.
Tourmaline Bio's investors include RA Capital Management, Vivo Capital, TCG Crossover, Great Point Partners, Cowen Healthcare Investments.
Tourmaline Bio is headquartered in New York, United States.
Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.
Tourmaline Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tourmaline Bio — Funding & Investors." VCBacked, January 25, 2024, https://www.vcbacked.co/company/tourmaline-bio. Accessed July 20, 2026.
VCBacked. (2024). Tourmaline Bio — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/tourmaline-bio
{{cite web |title=Tourmaline Bio — Funding & Investors |url=https://www.vcbacked.co/company/tourmaline-bio |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated